<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210904052371N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-20</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of The Efficacy And Side Effects of Combined Doses of Dexmedetomidine And Propofol With Isoflurane And Nitrosoxide as a General Anesthetic Preservative in Orthopedic Surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of The Efficacy And Side Effects of Combined Doses of Dexmedetomidine And Propofol With Isoflurane And Nitrosoxide as a General Anesthetic Preservative in Orthopedic Surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64092</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients who meet the inclusion criteria are randomly assigned (using a table of random numbers) to three groups A, B and C (30 people in each group). The anesthesia assistant will not know the study groups and the dose of IV and inhaled drugs. The drugs will be prepared by an anesthesiologist using labels A, B and C. They will be provided to the anesthesia assistant in the lower year. B Patients will undergo complete intravenous anesthesia using the maximum combined dose of propofol and dexmedetomidine. In group C, patients will undergo inhalation anesthesia using isoflurane and nitrous oxide, Blinding description: The present study will be conducted in a double-blind method, so that neither patients nor the evaluators of the study outcomes are aware of the placement of patients in the study groups. In addition, fair people are placed in groups. Syringes prepared with different concentrations that have reached the same volumes with normal saline for bolus injection and
Prepared microstructures with different concentrations (2 groups of maximum and minimum dose) that have reached the same volumes with normal saline, for infusion during operation
 A low-year resident or anesthesiologist present at the patient's bedside who do not know the concentration of the drug
And record only clinical signs and vital signs.</study_design>
      <phase>3</phase>
      <hc_freetext>Depth of anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group (A) for dexmedetomidine will use an initial bolus dose (0.5 μg / kg) over 10 minutes and a maintenance dose (0.5 μg / kg / h). Propofol will also be used in bolus dose (0.25 mg / kg) and maintenance dose (0.25 mg / kg / h). Propofol ampoule from Dongkook Pharaceutical COtd-company Korea and dexmedetomidine ampoules EXIR manufacturer Iran. Intervention 2: Intervention group: Group (B) for dexmedetomidine will use an initial bolus dose (1 μg / kg) over 10 minutes and a maintenance dose (1 μg / kg / h). Propofol will also be used in bolus dose (1.5 mg / kg) and maintenance dose (5 mg / kg / h). In each of these groups, dexmedetomidine and propofol are combined and given to the patient. Intervention 3: Control group: To maintain anesthesia, only N2O 50% anesthetics and MAC isoflurane 1 will be used. N2O gas capsule made in Iran and Bethlehem company and isoflurane solution made in USA and from Piramel Critical care company, INC.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Goli Azzi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Amir Mazandarani St. Imam Khomeini Hospital</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48166-33131</zip>
        <telephone>+98 11 3336 1700</telephone>
        <email>Gaezi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Goli Azzi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Amir Mazandarani St. Imam Khomeini Hospital</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48166-33131</zip>
        <telephone>+98 11 3336 1700</telephone>
        <email>Gaezi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient's desire to participate in the study and gain informed consent
Candidate for non-emergency orthopedic surgery under general anesthesia
Age between 18-60 years
Class 1 and 2 Anesthesia (ASA)
Patients who do not have complications such as hypotension, hypertension, bradycardia, pneumothorax, air embolism and decreased arterial oxygen saturation, which is a possible side effect of anesthetics</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Emergency surgery
Known allergies to the drugs used in the present study
Operation longer than 5 hours
Patients during the intervention if acute complications such as hypotension, hypertension, bradycardia, pneumothorax, air embolism and a decrease in arterial oxygen saturation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y84</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group (A) for dexmedetomidine will use an initial bolus dose (0.5 μg / kg) over 10 minutes and a maintenance dose (0.5 μg / kg / h). Propofol will also be used in bolus dose (0.25 mg / kg) and maintenance dose (0.25 mg / kg / h). Propofol ampoule from Dongkook Pharaceutical COtd-company Korea and dexmedetomidine ampoules EXIR manufacturer Iran</i_keyword>
      <i_keyword>Intervention group: Group (B) for dexmedetomidine will use an initial bolus dose (1 μg / kg) over 10 minutes and a maintenance dose (1 μg / kg / h). Propofol will also be used in bolus dose (1.5 mg / kg) and maintenance dose (5 mg / kg / h). In each of these groups, dexmedetomidine and propofol are combined and given to the patient.</i_keyword>
      <i_keyword>Control group: To maintain anesthesia, only N2O 50% anesthetics and MAC isoflurane 1 will be used. N2O gas capsule made in Iran and Bethlehem company and isoflurane solution made in USA and from Piramel Critical care company, INC</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Time to wake up from anesthesia. Timepoint: From the moment of closing the anesthetic (inhaled or intravenous) to the moment of waking the patient if the patient is able to obey instructions and communicate. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Depth of anesthesia. Timepoint: Immediately before and after induction (before starting maintenance dose), while receiving maintenance dose, when discontinuing anesthesia, moment of awakening from anesthesia, end of recovery. Method of measurement: brain function assessment.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-13</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Mazandaran University of Medical Sciences Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
